The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer
Official Title: Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer: Impact on Risk Estimates, Management Recommendations, Clinical Outcomes, and Patient Perception
Study ID: NCT03688204
Brief Summary: This study aims to assess how a polygenic risk score (PRS) reported with the results of multi-gene panel testing affects the breast cancer risk management recommendations healthcare providers make to their patients. The PRS is a score based on small genetic changes, clinical history, and family history. The PRS is used to estimate remaining lifetime risk of developing breast cancer for patients with no personal history of breast cancer and an overall negative result from MGPT.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Providence Roy and Patricia Disney Family Cancer Center, Burbank, California, United States
St Joseph Hospital of Orange, Orange, California, United States
Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States
Name: Brigette Tippin-Davis, PhD
Affiliation: Ambry Genetics
Role: STUDY_DIRECTOR